Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
Completed · Phase 2
Conditions studied: Mixed Gliomas
In brief
RATIONALE: Current therapies for adults with recurrent or refractory mixed gliomas provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of adults with recurrent or refractory mixed gliomas. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on adults with recurrent or refractory mixed gliomas.
Key facts
- Study ID
- NCT00003473
- Run by
- Burzynski Research Institute
- People needed
- 20
- Starts
- 1996-03-01
- Expected to finish
- 2007-08-01
- Last updated by the study team
- 2018-01-17
Who can join
Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Burzynski Clinic — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.